Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Core Insights - ZORYVE foam, a topical treatment for seborrheic dermatitis, has received strong endorsement from an expert dermatologist panel, indicating its suitability for diverse skin and hair types [1][3] - The formulation of ZORYVE foam is designed to be gentle and free from harmful ingredients, making it a versatile option for patients with various hair care practices [2][3] - ZORYVE foam is the first drug with a new mechanism of action approved for seborrheic dermatitis in over two decades, targeting the underlying inflammatory processes [5] Company Overview - Arcutis Biotherapeutics, Inc. is focused on developing innovative treatments for immune-mediated dermatological diseases, with a growing portfolio that includes FDA-approved products [8] - The company aims to address persistent patient challenges in dermatology through its unique development platform and expertise [8] Product Details - ZORYVE foam (roflumilast) is indicated for the treatment of seborrheic dermatitis in patients aged 9 years and older [6] - The foam formulation is a once-daily, steroid-free treatment that effectively delivers therapeutic agents to affected areas, including the scalp [1][5] - The formulation includes Crodafos CES, a gentle emulsifier that enhances compatibility with various skin and hair types [2][3]